AAS
GRCE

Avantax Advisory Services’s Grace Therapeutics GRCE Stock Holding History

Avantax Advisory Services’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-349
Closed -$3K – 1377
2020
Q3 		$3K Buy
+349
New +$9.06K ﹤0.01% 1375

Other funds holding GRCE

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
OC
Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MMPW
Mitchell McLeod Pugh & Williams Mobile, Alabama $678M AUM 23.02% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Avantax Advisory Services's GRCE Position: Q4 2020 in Review

Avantax Advisory Services sold out of Grace Therapeutics (GRCE) in Q4 2020, closing a stake of 349 shares — an estimated $3K sold.

Avantax Advisory Services first reported a position in GRCE in Q3 2020 and held it in 1 quarter. The position peaked at $3K in Q3 2020. 28 funds tracked by Wall St. Rank hold GRCE as of Q4 2020.

  • Avantax Advisory Services reported no remaining Grace Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Avantax Advisory Services sold 349 Grace Therapeutics shares in Q4 2020, an estimated $3K.
  • Avantax Advisory Services first reported a position in Grace Therapeutics in Q3 2020 and held it in 1 quarter.
  • Avantax Advisory Services's Grace Therapeutics position peaked at $3K in Q3 2020.
  • 28 funds tracked by Wall St. Rank held Grace Therapeutics as of Q4 2020.

Based on Avantax Advisory Services's 13F filing for Q4 2020, filed 22 Jan 2021.